Shares of Xeris Pharmaceuticals Inc (NASDAQ:XERS) have been assigned an average rating of “Buy” from the six analysts that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $24.50.
A number of research analysts have weighed in on the stock. Mizuho reiterated a “buy” rating and set a $27.00 price objective on shares of Xeris Pharmaceuticals in a research report on Tuesday, December 4th. Zacks Investment Research cut shares of Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, January 12th. Finally, ValuEngine cut shares of Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, December 18th.
Xeris Pharmaceuticals stock opened at $9.54 on Tuesday. The firm has a market cap of $260.86 million and a P/E ratio of -1.91. The company has a current ratio of 11.59, a quick ratio of 11.59 and a debt-to-equity ratio of 0.42. Xeris Pharmaceuticals has a 52-week low of $8.67 and a 52-week high of $27.98.
Xeris Pharmaceuticals (NASDAQ:XERS) last released its quarterly earnings results on Wednesday, March 6th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.94) by ($0.04). The company had revenue of $0.80 million for the quarter, compared to the consensus estimate of $0.10 million. On average, equities research analysts predict that Xeris Pharmaceuticals will post -3.28 earnings per share for the current fiscal year.
In other Xeris Pharmaceuticals news, insider James E. Flynn sold 114,444 shares of the business’s stock in a transaction on Friday, January 25th. The shares were sold at an average price of $15.43, for a total transaction of $1,765,870.92. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Redmile Group, Llc acquired 588,000 shares of the business’s stock in a transaction on Tuesday, February 19th. The shares were purchased at an average price of $10.00 per share, for a total transaction of $5,880,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 620,500 shares of company stock worth $6,178,600 and have sold 159,250 shares worth $2,452,644.
A number of hedge funds have recently bought and sold shares of the business. Northern Trust Corp increased its position in Xeris Pharmaceuticals by 1.5% during the fourth quarter. Northern Trust Corp now owns 74,423 shares of the company’s stock valued at $1,265,000 after acquiring an additional 1,089 shares during the last quarter. New York State Common Retirement Fund bought a new position in Xeris Pharmaceuticals during the fourth quarter valued at $66,000. Bank of New York Mellon Corp increased its position in Xeris Pharmaceuticals by 33.7% during the fourth quarter. Bank of New York Mellon Corp now owns 19,941 shares of the company’s stock valued at $339,000 after acquiring an additional 5,027 shares during the last quarter. Geode Capital Management LLC increased its position in Xeris Pharmaceuticals by 23.0% during the fourth quarter. Geode Capital Management LLC now owns 82,692 shares of the company’s stock valued at $1,405,000 after acquiring an additional 15,459 shares during the last quarter. Finally, BlackRock Inc. bought a new position in shares of Xeris Pharmaceuticals in the second quarter worth about $475,000. Institutional investors and hedge funds own 51.68% of the company’s stock.
Xeris Pharmaceuticals Company Profile
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Featured Article: Index Funds
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.